Research programme: tau protein targeting therapeutics - Cantabio Pharmaceuticals/University of Cambridge

Drug Profile

Research programme: tau protein targeting therapeutics - Cantabio Pharmaceuticals/University of Cambridge

Alternative Names: CB 401; Chaperone-based therapeutics - Cantabio Pharmaceuticals/University of Cambridge; Tau protein modulators - Cantabio Pharmaceuticals/University of Cambridge

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
  • Developer Cantabio Pharmaceuticals; Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia

Most Recent Events

  • 07 Sep 2016 Tau protein targeting therapeutics licensed to Cantabio Pharmaceuticals worldwide for the treatment of Alzheimer's disease and Demntia
  • 07 Sep 2016 Preclinical trials of CB 401 in Alzheimer's disease in USA (unspecified route) (Cantabio pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top